Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis.
about
Certolizumab pegol (CDP870) for rheumatoid arthritis in adultsCertolizumab pegol (CDP870) for rheumatoid arthritis in adultsCertolizumab pegolExperiences of mobility for people living with rheumatoid arthritis who are receiving biologic drug therapy: implications for podiatry services.Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA studyWork-related outcomes in randomised placebo-controlled pain trials: a systematic review and meta-analysisPhysical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegolRapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized contDiscriminant validity, responsiveness and reliability of the arthritis-specific Work Productivity Survey assessing workplace and household productivity in patients with psoriatic arthritisCertolizumab pegol in the treatment of rheumatoid arthritis: a comprehensive review of its clinical efficacy and safety.The efficacy and safety of certolizumab pegol (CZP) in the treatment of active rheumatoid arthritis (RA): a meta-analysis from nine randomized controlled trials.Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised plaCertolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trialDiscriminant validity, responsiveness and reliability of the arthritis-specific Work Productivity Survey assessing workplace and household productivity within and outside the home in patients with axial spondyloarthritis, including nonradiographic aWork productivity in scleroderma: analysis from the University of California, Los Angeles scleroderma quality of life study.Cost-utility analysis of certolizumab pegol versus alternative tumour necrosis factor inhibitors available for the treatment of moderate-to-severe active rheumatoid arthritis in Spain.Decision tool to improve the quality of care in rheumatoid arthritisPrefilled certolizumab pegol (Cimzia(®)) syringes for self-use in the treatment of rheumatoid arthritisCertolizumab in the long-term treatment of rheumatoid arthritis.Certolizumab pegol: a new biologic targeting rheumatoid arthritis.The clinical efficacy and safety of certolizumab pegol in rheumatoid arthritis.RAPID and FAST4WARD trials: certolizumab pegol for rheumatoid arthritis.Indirect comparison of biological treatments in refractory rheumatoid arthritis.Interpreting clinical trial results for moderate-to-severe rheumatoid arthritis: practical applications for rheumatology healthcare providers.Certolizumab pegol for the treatment of rheumatoid arthritis.Measures of work disability and productivity: Rheumatoid Arthritis Specific Work Productivity Survey (WPS-RA), Workplace Activity Limitations Scale (WALS), Work Instability Scale for Rheumatoid Arthritis (RA-WIS), Work Limitations Questionnaire (WLQCertolizumab pegol: a review of its use in the management of rheumatoid arthritis.Certolizumab pegol in axial spondyloarthritis.Efficacy and safety of certolizumab pegol in rheumatoid arthritis: meeting rheumatologists' requirements in routine clinical practice.Certolizumab Pegol: A Review in Inflammatory Autoimmune Diseases.Effect of adalimumab on the work-related outcomes scores in patients with early rheumatoid arthritis receiving methotrexate.Rheumatoid arthritis is still expensive in the new decade: a comparison between two early RA cohorts, diagnosed 1996-98 and 2006-09.American College of Rheumatology 2015 Annual Meeting.The high cost of spasticity in multiple sclerosis to individuals and society.Guidelines for the drug treatment of rheumatoid arthritis.Costs of rheumatoid arthritis during the period 1990-2010: a register-based cost-of-illness study in Sweden.Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.Work productivity loss in early arthritis during the first 3 years of disease: a study from a French National Multicenter Cohort.Improvements in workplace and household productivity with certolizumab pegol treatment in axial spondyloarthritis: results to week 96 of a phase III study.
P2860
Q24193535-F15BD876-1392-4EE9-897D-572140A1F82EQ24236701-BCEA76CE-E43A-4625-87AD-014D88E8A336Q24625401-93DE5E2D-C270-459D-AC90-A281DFAAFC35Q30842186-8F06B737-EE1A-4D20-BA3E-37E27904937BQ33540305-3EFFA75C-FE3F-4CB1-AD46-E9FDF839B219Q33936266-FF1B962F-6B76-4F32-ADF1-1435BCBE26EEQ34117111-51B73443-A738-43C5-890F-41F43D9EB09DQ34413310-8890F9BC-530C-478C-AC76-2DBE2DFB6BF1Q34485175-A0AA7503-0B7A-46E2-848F-712FCECE4573Q34495874-0208E2E7-8183-4A73-A2FE-7502EAB3AE27Q34769757-6945755F-D34D-47D0-901A-5A002839D877Q34818891-111F4F81-FD16-4D12-91C2-11088AE3502CQ35351313-0472F54C-0543-407E-AEF5-3D2ACC5BF0C2Q35664666-D4C9213C-1CCD-4B3A-9ED0-A7D466D94077Q35700148-5312984C-869D-4F65-AD83-2A28EF0C976BQ35795354-02DF8388-32FB-4933-939A-6A13A510E489Q36032715-3BAE6EF0-766E-4580-BBF3-BF3617FADB22Q36160421-804B4257-EAB1-4637-A08F-13F3983B7E17Q37358254-C4019050-235A-4210-9B32-450BCD141B03Q37676988-4E1A6E08-F1A8-4E46-A41E-7C4541F6EAAAQ37709364-C98A304C-95E7-4C85-ABF5-1C2C0D7BE501Q37786625-7DA7D3C9-9C1F-40C6-A78D-27A64FFA432BQ37914956-652727D7-33C4-456A-9901-05725C44E052Q37928726-150E1663-F8DD-40F0-B9F6-F650AAE39E36Q37967946-0D65D597-CDB9-48F7-941D-DF2A2B18A692Q38010365-3D23241F-4701-4CBC-94D5-D9333ABCFFC6Q38075801-8EE8FCC9-D123-4358-81DE-A697E9255533Q38161555-0A439E52-1A6D-4EB8-AE1B-F65B7D896779Q38200927-507B6364-DD38-429F-9A9D-027F51B3035EQ38972531-3FA5FF0A-5194-40CE-B1F8-FD22FF6A95E1Q39821943-CBEA73B1-DF4B-4F1A-9A22-C6E27C2D84CBQ40015472-29CC83D3-428D-459E-AC8F-AEA3683E9DE1Q41301506-8C0D1815-B3C2-4F5B-8268-C798DB9CF4DBQ41523590-7EF2140C-025D-46FE-8212-A88C8BDF25DAQ43675571-E17A6670-00CA-40BF-BD1E-EB6FF98FAD9DQ44918475-88FC1099-3C57-4D09-A892-1B36608F91F6Q47836056-E1DD0B08-6B87-44FB-B8DC-F5CBEC76A885Q50661536-A5C9BC6C-A8E2-4DA3-A7BA-6A1A44ED9DE6Q53829185-2FB3A4EB-5DCB-4E4E-AF9C-D4F66C060DC8
P2860
Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Effect of certolizumab pegol w ...... h active rheumatoid arthritis.
@en
Effect of certolizumab pegol w ...... h active rheumatoid arthritis.
@en-gb
Effect of certolizumab pegol w ...... h active rheumatoid arthritis.
@nl
type
label
Effect of certolizumab pegol w ...... h active rheumatoid arthritis.
@en
Effect of certolizumab pegol w ...... h active rheumatoid arthritis.
@en-gb
Effect of certolizumab pegol w ...... h active rheumatoid arthritis.
@nl
prefLabel
Effect of certolizumab pegol w ...... h active rheumatoid arthritis.
@en
Effect of certolizumab pegol w ...... h active rheumatoid arthritis.
@en-gb
Effect of certolizumab pegol w ...... h active rheumatoid arthritis.
@nl
P2093
P50
P356
P1476
Effect of certolizumab pegol w ...... h active rheumatoid arthritis.
@en
P2093
Arthur Kavanaugh
Edward Keystone
Lance Richard
Oana Purcaru
Vibeke Strand
P304
P356
10.1002/ART.24828
P577
2009-11-01T00:00:00Z
P5875
P6179
1003086691